omapatrilat (BioDeep_00000767581)
代谢物信息卡片
omapatrilat
化学式: C19H24N2O4S2 (408.1177424)
中文名称: 奥马曲拉
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC(N2C(C1)SCCC(C2=O)NC(=O)C(CC3=CC=CC=C3)S)C(=O)O
InChI: InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1
描述信息
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:135660
- KEGGdrug: D01970
- PubChem: 656629
- DrugBank: DB00886
- ChEMBL: CHEMBL289556
- CAS: 167305-00-2
- CAS: 159317-63-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- R Murray McKinnell, Paul Fatheree, Seok-Ki Choi, Roland Gendron, Keith Jendza, Brooke Olson Blair, Joe Budman, Craig M Hill, Laxminarayan G Hegde, Cecile Yu, Donavon McConn, Sharath S Hegde, Daniel G Marquess, Uwe Klein. Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI).
ACS medicinal chemistry letters.
2019 Jan; 10(1):86-91. doi:
10.1021/acsmedchemlett.8b00462. [PMID: 30655952] - Laura Grois, Julian Hupf, Jörg Reinders, Josef Schröder, Alexander Dietl, Peter M Schmid, Carsten Jungbauer, Markus Resch, Lars S Maier, Andreas Luchner, Christoph Birner. Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure.
PloS one.
2017; 12(1):e0169743. doi:
10.1371/journal.pone.0169743. [PMID: 28076404] - Scott A Hubers, Nancy J Brown. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Circulation.
2016 Mar; 133(11):1115-24. doi:
10.1161/circulationaha.115.018622. [PMID: 26976916] - Harold Smulyan, Saktipada Mookherjee, Michel E Safar. The two faces of hypertension: role of aortic stiffness.
Journal of the American Society of Hypertension : JASH.
2016 Feb; 10(2):175-83. doi:
10.1016/j.jash.2015.11.012. [PMID: 26725014] - Parminder Judge, Richard Haynes, Martin J Landray, Colin Baigent. Neprilysin inhibition in chronic kidney disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2015 May; 30(5):738-43. doi:
10.1093/ndt/gfu269. [PMID: 25140014] - Olli Haltia, Suvi Törmänen, Arttu Eräranta, Jarkko Jokihaara, Klaus Nordhausen, Jaana Rysä, Heikki Ruskoaho, Ilkka Tikkanen, Jukka Mustonen, Ilkka Pörsti. Vasopeptidase Inhibition Corrects the Structure and Function of the Small Arteries in Experimental Renal Insufficiency.
Journal of vascular research.
2015; 52(2):94-102. doi:
10.1159/000431368. [PMID: 26184548] - Sarah Mangiafico, Lisa C Costello-Boerrigter, Ingrid A Andersen, Alessandro Cataliotti, John C Burnett. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.
European heart journal.
2013 Mar; 34(12):886-893c. doi:
10.1093/eurheartj/ehs262. [PMID: 22942338] - Christoph Birner, Coskun Ulucan, Mona Bratfisch, Tobias Götz, Alexander Dietl, Frank Schweda, Günter A Riegger, Andreas Luchner. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Naunyn-Schmiedeberg's archives of pharmacology.
2012 Nov; 385(11):1117-25. doi:
10.1007/s00210-012-0791-6. [PMID: 22895639] - Laxminarayan G Hegde, Cecile Yu, Travis Renner, Harold Thibodeaux, Scott R Armstrong, Timothy Park, Madhavi Cheruvu, Rachael Olsufka, Erik R Sandvik, Cassie E Lane, Joe Budman, Craig M Hill, Uwe Klein, Sharath S Hegde. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Journal of cardiovascular pharmacology.
2011 Apr; 57(4):495-504. doi:
10.1097/fjc.0b013e318210fc7e. [PMID: 21297495] - Toshio Nishikimi, Yosuke Mori, Kimihiko Ishimura, Yayoi Ishikawa, Shogo Koshikawa, Kazumi Akimoto, Naoto Minamino, Kenji Kangawa, Hiroaki Matsuoka. Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats.
American journal of hypertension.
2006 Oct; 19(10):1039-48. doi:
10.1016/j.amjhyper.2006.02.013. [PMID: 17027825] - César Ramírez-Molina, Olivier Heudi, Mark Pullen, Peter S Marshall. Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry.
Journal of peptide science : an official publication of the European Peptide Society.
2006 Mar; 12(3):220-6. doi:
10.1002/psc.712. [PMID: 16163665] - Anthony C Sulpizio, Mark A Pullen, Richard M Edwards, James B Louttit, Rob West, David P Brooks. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
The Journal of pharmacology and experimental therapeutics.
2005 Dec; 315(3):1306-13. doi:
10.1124/jpet.105.084749. [PMID: 16144980] - Kimihiko Ishimura, Toshio Nishikimi, Kazumi Akimoto, Hidehiko Ono, Kenji Kangawa, Hiroaki Matsuoka. Renoprotective effect of long-term combined treatment with adrenomedullin and omapatrilat in hypertensive rats.
Journal of hypertension.
2005 Dec; 23(12):2287-96. doi:
10.1097/01.hjh.0000188731.75592.eb. [PMID: 16269971] - N Basso, N Paglia, R Cini, F Inserra, N A Terragno. Effect of omapatrilat on the aging process of the normal rat.
Cellular and molecular biology (Noisy-le-Grand, France).
2005 Nov; 51(6):557-64. doi:
NULL. [PMID: 16309580] - Karin Jandeleit-Dahm, Markus Lassila, Belinda J Davis, Riccardo Candido, Colin I Johnston, Terri J Allen, Louise M Burrell, Mark E Cooper. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Journal of hypertension.
2005 Nov; 23(11):2071-82. doi:
10.1097/01.hjh.0000184747.41565.a1. [PMID: 16208151] - Farid Nakhoul, Rawi Ramadan, Eliyahu Khankin, Afif Yaccob, Zoya Kositch, Moshe Lewin, Suheir Assady, Zaid Abassi. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
American journal of physiology. Renal physiology.
2005 Oct; 289(4):F880-90. doi:
10.1152/ajprenal.00451.2004. [PMID: 15942045] - Zhong Jian Cheng, Tina Grönholm, Marjut Louhelainen, Piet Finckenberg, Saara Merasto, Ilkka Tikkanen, Eero Mervaala. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats.
Journal of hypertension.
2005 Sep; 23(9):1757-70. doi:
10.1097/01.hjh.0000179765.48324.b4. [PMID: 16093923] - Marie Eve Moreau, Nancy Garbacki, Giuseppe Molinaro, Nancy J Brown, François Marceau, Albert Adam. The kallikrein-kinin system: current and future pharmacological targets.
Journal of pharmacological sciences.
2005 Sep; 99(1):6-38. doi:
10.1254/jphs.srj05001x. [PMID: 16177542] - Tao Wang, Toshikazu Takabatake. Effects of vasopeptidase inhibition on renal function and tubuloglomerular feedback in spontaneously hypertensive rats.
Hypertension research : official journal of the Japanese Society of Hypertension.
2005 Jul; 28(7):611-8. doi:
10.1291/hypres.28.611. [PMID: 16335890] - Bernard R Chaitman, Alla Y Ivleva, Marek Ujda, Jacque H F Lenis, Csaba Toth, David M Stieber, Leonardo H Reisin, Andreas M Pangerl, Julie B Friedman, John H Lawrence. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris.
The American journal of cardiology.
2005 Jun; 95(11):1283-9. doi:
10.1016/j.amjcard.2005.01.069. [PMID: 15904630] - Qian Pu, Farhad Amiri, Philippe Gannon, Ernesto L Schiffrin. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
Journal of hypertension.
2005 Feb; 23(2):401-9. doi:
10.1097/00004872-200502000-00023. [PMID: 15662229] - Stefano Perlini. The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule.
Journal of hypertension.
2005 Feb; 23(2):273-5. doi:
10.1097/00004872-200502000-00007. [PMID: 15662213] - Zaid A Abassi, Ali Yahia, Samar Zeid, Tony Karram, Eliahu Golomb, Joseph Winaver, Aaron Hoffman. Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure.
American journal of physiology. Heart and circulatory physiology.
2005 Feb; 288(2):H722-8. doi:
10.1152/ajpheart.00737.2004. [PMID: 15498826] - Wei Jiang, Da-Yong Cai, Chun-Shui Pan, Yong-Fen Qi, Hong-Feng Jiang, Bing Geng, Chao-Shu Tang. Changes in production and metabolism of brain natriuretic peptide in rats with myocardial necrosis.
European journal of pharmacology.
2005 Jan; 507(1-3):153-62. doi:
10.1016/j.ejphar.2004.11.023. [PMID: 15659305] - E Kostova, E Jovanoska, D Zafirov, K Jakovski, V Maleska, M Slaninka-Miceska. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Bratislavske lekarske listy.
2005; 106(12):407-11. doi:
. [PMID: 16642666] - Bernard Jover, Luc Stuit, Albert Mimran. Systemic and renal effect of chronic omapatrilat in sodium-restricted, one-kidney, one-clip hypertensive rats.
Journal of hypertension.
2004 Feb; 22(2):383-8. doi:
10.1097/00004872-200402000-00024. [PMID: 15076198] - Sally A Mifsud, Louise M Burrell, Eiji Kubota, Kassie Jaworski, Mark E Cooper, Jennifer L Wilkinson-Berka. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2004 Jan; 26(1):69-80. doi:
10.1081/ceh-120027332. [PMID: 15000298] - Tony Hayek, Shadi Hamoud, Shlomo Keidar, Elsa Pavlotzky, Raymond Coleman, Michael Aviram, Marielle Kaplan. Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice.
Journal of cardiovascular pharmacology.
2004 Jan; 43(1):140-7. doi:
10.1097/00005344-200401000-00021. [PMID: 14668580] - Ahmed A Elmarakby, Peter Morsing, Jennifer S Pollock, David M Pollock. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats.
Vascular pharmacology.
2003 Dec; 40(5):253-9. doi:
10.1016/j.vph.2004.01.002. [PMID: 15259792] - Lu Ying, Martin Flamant, Sophie Vandermeersch, Jean-Jacques Boffa, Christos Chatziantoniou, Jean-Claude Dussaule, Dominique Chansel. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats.
Hypertension (Dallas, Tex. : 1979).
2003 Nov; 42(5):937-44. doi:
10.1161/01.hyp.0000099240.89890.94. [PMID: 14569001] - Olga González-Albarrán, Oscar Gómez, Esther Ruiz, Paula Vieitez, Rafael García-Robles. Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats).
American journal of hypertension.
2003 Nov; 16(11 Pt 1):979-85. doi:
10.1016/s0895-7061(03)01000-8. [PMID: 14573338] - Wei-Chi Liao, Ole Vesterqvist, Carol Delaney, Mohammed Jemal, Irene Ferreira, Neville Ford, Brian Swanson, Howard Uderman. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
British journal of clinical pharmacology.
2003 Oct; 56(4):395-406. doi:
10.1046/j.1365-2125.2003.01888.x. [PMID: 12968984] - Ulrich O Wenzel, Gunter Wolf, Ivonne Jacob, Christian Schwegler, Arish Qasqas, Kerstin Amann, Udo Helmchen, Rolf A K Stahl. Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2003 Oct; 18(10):2005-13. doi:
10.1093/ndt/gfg271. [PMID: 13679474] - Eiji Kubota, Rachael G Dean, Richard A Hubner, David J Casley, Colin I Johnston, Louise M Burrell. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
Clinical science (London, England : 1979).
2003 Sep; 105(3):339-45. doi:
10.1042/cs20030097. [PMID: 12741953] - Xiaoyan Zhou, Hidehiko Ono, Yuko Ono, Edward D Frohlich. Renoprotective effects of omapatrilat are mediated partially by bradykinin.
American journal of nephrology.
2003 Jul; 23(4):214-21. doi:
10.1159/000071507. [PMID: 12789027] - Zohar Levy, Ayana Dvir, Aviv Shaish, Svetlana Trestman, Hofit Cohen, Hana Levkovietz, Rita Rhachmani, Mordchai Ravid, Dror Harats. Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
International journal of experimental diabesity research.
2003 Jan; 4(1):59-64. doi:
10.1080/15438600303728. [PMID: 12745671] - Hong-Yun Wang, Yu-Fang Hu, Ji Jiang, Pei Hu. Quantitative determination of omapatrilat and its metabolites in human plasma by HPLC coupled with tandem mass spectrometry.
Acta pharmacologica Sinica.
2003 Jan; 24(1):74-84. doi:
NULL. [PMID: 12511233] - Ramaswamy A Iyer, Bimal Malhotra, Sanaullah Khan, James Mitroka, Samuel Bonacorsi, Stephen C Waller, J Kent Rinehart, Kishin Kripalani. Comparative biotransformation of radiolabeled [(14)C]omapatrilat and stable-labeled [(13)C(2)]omapatrilat after oral administration to rats, dogs, and humans.
Drug metabolism and disposition: the biological fate of chemicals.
2003 Jan; 31(1):67-75. doi:
10.1124/dmd.31.1.67. [PMID: 12485955] - Isabel Rodriguez-Gomez, Rosemary Wangensteen, Noemi M Atucha, Francisco O'Valle, Raimundo G Del Moral, Joaquin Garcia-Estañ, Felix Vargas, Antonio Osuna. Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats.
American journal of hypertension.
2003 Jan; 16(1):33-8. doi:
10.1016/s0895-7061(02)03144-8. [PMID: 12517680] - Bruce Neal, Stephen MacMahon, Takayoshi Ohkubo, Alan Brnabic, Andrew Tonkin. Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2002 Dec; 3(4):270-6. doi:
10.3317/jraas.2002.049. [PMID: 12584671] - Olivier Heudi, Cesar Ramirez-Molina, Peter Marshall, Augustin Amour, Simon Peace, Stephen McKeown, Fadi Abou-Shakra. Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.
Journal of peptide science : an official publication of the European Peptide Society.
2002 Nov; 8(11):591-600. doi:
10.1002/psc.419. [PMID: 12487427] - Carlos M Ferrario, David B Averill, K Bridget Brosnihan, Mark C Chappell, Samy S Iskandar, Richard H Dean, Debra I Diz. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat.
Kidney international.
2002 Oct; 62(4):1349-57. doi:
10.1111/j.1523-1755.2002.kid559.x. [PMID: 12234305] - Michel Azizi, Maxime Lamarre-Cliche, Agnès Labatide-Alanore, Alvine Bissery, Than Tam Guyene, Joël Ménard. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Journal of the American Society of Nephrology : JASN.
2002 Oct; 13(10):2454-63. doi:
10.1097/01.asn.0000030142.80452.11. [PMID: 12239234] - Calin V Maniu, Donna M Meyer, Margaret M Redfield. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Hypertension (Dallas, Tex. : 1979).
2002 Oct; 40(4):528-34. doi:
10.1161/01.hyp.0000033223.17484.b1. [PMID: 12364358] - Bruce Neal, Stephen MacMahon, Takayoshi Ohkubo, Andrew Tonkin, David Wilcken. Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease.
European heart journal.
2002 Oct; 23(19):1509-15. doi:
10.1053/euhj.2002.3161. [PMID: 12395803] - Frédéric Regamey, Marc Maillard, Jürg Nussberger, Hans R Brunner, Michel Burnier. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Hypertension (Dallas, Tex. : 1979).
2002 Sep; 40(3):266-72. doi:
10.1161/01.hyp.0000030178.90322.11. [PMID: 12215465] - Dougal R McClean, Hamid Ikram, Sukh Mehta, J Thomas Heywood, Michel F Rousseau, Alan L Niederman, Rafael F Sequeira, Eckart Fleck, Steven N Singh, Benoit Coutu, Peter Hanrath, Michel Komajda, Catherine C Bryson, Chunlin Qian, James J Hanyok. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
Journal of the American College of Cardiology.
2002 Jun; 39(12):2034-41. doi:
10.1016/s0735-1097(02)01881-8. [PMID: 12084605] - Carlos M Ferrario, Ronald D Smith, Bridget Brosnihan, Mark C Chappell, Vito M Campese, Ole Vesterqvist, Wei-chi Liao, Michael C Ruddy, Clarence E Grim. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
American journal of hypertension.
2002 Jun; 15(6):557-64. doi:
10.1016/s0895-7061(02)02268-9. [PMID: 12074359] - Horng H Chen, John G Lainchbury, Gail J Harty, John C Burnett. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
Circulation.
2002 Feb; 105(8):999-1003. doi:
10.1161/hc0802.104282. [PMID: 11864932] - Alessandro Cataliotti, Guido Boerrigter, Horng H Chen, Michihisa Jougasaki, Lisa C Costello, Toshihiro Tsuruda, Shang-Chiun Lee, Lorenzo S Malatino, John C Burnett. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Circulation.
2002 Feb; 105(5):639-44. doi:
10.1161/hc0502.102962. [PMID: 11827932] - John S Floras. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
The Canadian journal of cardiology.
2002 Feb; 18(2):177-82. doi:
NULL. [PMID: 11875587] - H H Chen, A Cataliotti, J C Burnett. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
Current hypertension reports.
2001 Dec; 3 Suppl 2(?):S15-21. doi:
10.1007/s11906-001-0102-y. [PMID: 11716801] - H Uderman, O Vesterqvist, J Manning, I Ferreira, C Delaney, W C Liao. Omapatrilat: neurohormonal and pharmacodynamic profile when administered with furosemide.
Journal of clinical pharmacology.
2001 Dec; 41(12):1291-300. doi:
10.1177/00912700122012878. [PMID: 11762556] - J B Kostis, M Klapholz, C Delaney, O Vesterqvist, M Cohen, J A Manning, M Jemal, G D Kollia, W C Liao. Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure.
Journal of clinical pharmacology.
2001 Dec; 41(12):1280-90. doi:
10.1177/00912700122012869. [PMID: 11762555] - V M Campese, K C Lasseter, C M Ferrario, W B Smith, M C Ruddy, C E Grim, R D Smith, R Vargas, M F Habashy, O Vesterqvist, C L Delaney, W C Liao. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.
Hypertension (Dallas, Tex. : 1979).
2001 Dec; 38(6):1342-8. doi:
10.1161/hy1201.096569. [PMID: 11751715] - M Jemal, S Khan, D S Teitz, J A McCafferty, D J Hawthorne. LC/MS/MS determination of omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor, and its sulfhydryl- and thioether-containing metabolites in human plasma.
Analytical chemistry.
2001 Nov; 73(22):5450-6. doi:
10.1021/ac010532d. [PMID: 11816572] - T Bäcklund, E Palojoki, T Grönholm, A Eriksson, O Vuolteenaho, M Laine, I Tikkanen. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
Pharmacological research.
2001 Nov; 44(5):411-8. doi:
10.1006/phrs.2001.0875. [PMID: 11712872] - Thomas Quaschning, Livius V D'Uscio, Sidney Shaw, Hermann-Josef Gröne, Frank Ruschitzka, Thomas F Lüscher. Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension.
Journal of the American Society of Nephrology : JASN.
2001 Nov; 12(11):2280-2287. doi:
10.1681/asn.v12112280. [PMID: 11675404] - Maarten W Taal, Vesselin D Nenov, Waichi Wong, Sharad R Satyal, Olga Sakharova, Jeong Hoon Choi, Julia L Troy, Barry M Brenner. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone.
Journal of the American Society of Nephrology : JASN.
2001 Oct; 12(10):2051-2059. doi:
10.1681/asn.v12102051. [PMID: 11562403] - M Klapholz, I Thomas, C Eng, B J Iteld, G A Ponce, A L Niederman, M Bilsker, J T Heywood, D Synhorst. Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
The American journal of cardiology.
2001 Sep; 88(6):657-61. doi:
10.1016/s0002-9149(01)01809-4. [PMID: 11564390] - K C Ferdinand. Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor.
Journal of clinical hypertension (Greenwich, Conn.).
2001 Sep; 3(5):307-12. doi:
10.1111/j.1524-6175.2001.00488.x. [PMID: 11588409] - F Ruschitzka, R Corti, T Quaschning, M Hermann, T F Lüscher. Vasopeptidase inhibitors--concepts and evidence.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2001 Aug; 16(8):1532-5. doi:
10.1093/ndt/16.8.1532. [PMID: 11477147] - K Ferdinand, R Saini, A Lewin, L Yellen, J A Barbosa, E Kushnir. Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone.
American journal of hypertension.
2001 Aug; 14(8 Pt 1):788-93. doi:
10.1016/s0895-7061(01)01294-8. [PMID: 11497195] - Z Cao, L M Burrell, I Tikkanen, F Bonnet, M E Cooper, R E Gilbert. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Kidney international.
2001 Aug; 60(2):715-21. doi:
10.1046/j.1523-1755.2001.060002715.x. [PMID: 11473654] - H H Chen, J G Lainchbury, Y Matsuda, G J Harty, J C Burnett . Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
Hypertension (Dallas, Tex. : 1979).
2001 Aug; 38(2):187-91. doi:
10.1161/01.hyp.38.2.187. [PMID: 11509474] - B K Malhotra, R A Iyer, K M Soucek, D Behr, W C Liao, J G Mitroka, S Kaul, M B Cohen, C A Knupp. Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.
Journal of clinical pharmacology.
2001 Aug; 41(8):833-41. doi:
10.1177/00912700122010726. [PMID: 11504270] - T Quaschning, L V d'Uscio, S Shaw, H Viswambharan, F T Ruschitzka, T F Lüscher. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2001 Jun; 16(6):1176-82. doi:
10.1093/ndt/16.6.1176. [PMID: 11390717] - R N Patel. Enzymatic synthesis of chiral intermediates for Omapatrilat, an antihypertensive drug.
Biomolecular engineering.
2001 Jun; 17(6):167-82. doi:
10.1016/s1389-0344(01)00068-5. [PMID: 11337276] - P O'Grady, O Vesterqvist, B Malhotra, J Manning, M Jemal, G Ge, B Mangold. Omapatrilat in patients with hepatic cirrhosis. Pharmacodynamics and pharmacokinetics.
European journal of clinical pharmacology.
2001 Jun; 57(3):249-57. doi:
10.1007/s002280100291. [PMID: 11497341] - J F Arnal, C Castano, E Maupas, A Mugniot, B Darblade, P Gourdy, J B Michel, F Bayard. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Atherosclerosis.
2001 Apr; 155(2):291-5. doi:
10.1016/s0021-9150(00)00565-7. [PMID: 11254898] - D R McClean, H Ikram, A H Garlick, I G Crozier. Effects of omapatrilat on systemic arterial function in patients with chronic heart failure.
The American journal of cardiology.
2001 Mar; 87(5):565-9. doi:
10.1016/s0002-9149(00)01432-6. [PMID: 11230840] - C A Aguilar-Salinas, S A Arellano, O Villanueva-Sanchez, G A Magos, L E Guillén-Pineda, R Rodriguez, F J Gómez-Pérez. Effects of omapatrilat on blood pressure and insulin sensitivity in an animal model of insulin resistance.
Blood pressure.
2001; 10(3):164-9. doi:
10.1080/080370501753182389. [PMID: 11688764] - P Morazo, L A Fortepiani, M Clara Ortíz, N M Atucha, J García-Estañ. Omapatrilat normalizes renal function curve in spontaneously hypertensive rats.
BMC pharmacology.
2001; 1(?):5. doi:
10.1186/1471-2210-1-5. [PMID: 11592920] - R A Iyer, J Mitroka, B Malhotra, S Bonacorsi, S C Waller, J K Rinehart, V A Roongta, K Kripalani. Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2001 Jan; 29(1):60-9. doi:
NULL. [PMID: 11124231] - D J van Veldhuisen, W H van Gilst. Vasopeptidase inhibition in heart failure.
Lancet (London, England).
2000 Oct; 356(9240):1526. doi:
10.1016/s0140-6736(05)73277-3. [PMID: 11081561] - L M Burrell, J Droogh, O Man in't Veld, M D Rockell, N K Farina, C I Johnston. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
American journal of hypertension.
2000 Oct; 13(10):1110-6. doi:
10.1016/s0895-7061(00)01185-7. [PMID: 11041166] - R W Troughton, M T Rademaker, J D Powell, T G Yandle, E A Espiner, C M Frampton, M G Nicholls, A M Richards. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
Hypertension (Dallas, Tex. : 1979).
2000 Oct; 36(4):523-30. doi:
10.1161/01.hyp.36.4.523. [PMID: 11040230] - D A Sica, W Liao, T W Gehr, S Khan, M Jemal, C L Delaney, I M Ferreira, B K Malhotra. Disposition and safety of omapatrilat in subjects with renal impairment.
Clinical pharmacology and therapeutics.
2000 Sep; 68(3):261-9. doi:
10.1067/mcp.2000.109033. [PMID: 11014407] - D R McClean, H Ikram, A H Garlick, A M Richards, M G Nicholls, I G Crozier. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure.
Journal of the American College of Cardiology.
2000 Aug; 36(2):479-86. doi:
10.1016/s0735-1097(00)00741-5. [PMID: 10933361] - M Azizi, C Massien, A Michaud, P Corvol. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
Hypertension (Dallas, Tex. : 1979).
2000 Jun; 35(6):1226-31. doi:
10.1161/01.hyp.35.6.1226. [PMID: 10856268] - A Dendorfer, P Dominiak. Vasopeptidase inhibition as a new concept in antihypertensive therapy.
Kidney & blood pressure research.
2000; 23(3-5):178-9. doi:
NULL. [PMID: 11031714] - C Massien, M Azizi, T T Guyene, O Vesterqvist, B Mangold, J Ménard. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Clinical pharmacology and therapeutics.
1999 Apr; 65(4):448-59. doi:
10.1016/s0009-9236(99)70140-2. [PMID: 10223783] - M Jemal, D J Hawthorne. Quantitative determination of BMS-186716, a thiol compound, in rat plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after hydrolysis of the methyl acrylate adduct by the native esterases.
Journal of chromatography. B, Biomedical sciences and applications.
1997 Sep; 698(1-2):123-32. doi:
10.1016/s0378-4347(97)00292-2. [PMID: 9367200] - M Jemal, D J Hawthorne. Quantitative determination of BMS186716, a thiol compound, in dog plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after formation of the methyl acrylate adduct.
Journal of chromatography. B, Biomedical sciences and applications.
1997 May; 693(1):109-16. doi:
10.1016/s0378-4347(97)00044-3. [PMID: 9200524] - J A Robl, C Q Sun, J Stevenson, D E Ryono, L M Simpkins, M P Cimarusti, T Dejneka, W A Slusarchyk, S Chao, L Stratton, R N Misra, M S Bednarz, M M Asaad, H S Cheung, B E Abboa-Offei, P L Smith, P D Mathers, M Fox, T R Schaeffer, A A Seymour, N C Trippodo. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Journal of medicinal chemistry.
1997 May; 40(11):1570-7. doi:
10.1021/jm970041e. [PMID: 9171867]